Amylyx to Seek AMX0035’s Approval in Europe

Amylyx to Seek AMX0035’s Approval in Europe

291807

Amylyx to Seek AMX0035’s Approval in Europe

Amylyx Pharmaceuticals is planning to file an application by the end of this year requesting that the European Medicines Agency (EMA) approve AMX0035 as an oral treatment for amyotrophic lateral sclerosis (ALS). This follows a recent announcement that a similar application will be submitted to Health Canada in the second half of the year. “We are thrilled to plan our submissions in Europe and Canada and will continue working closely with regulators and the ALS…

You must be logged in to read/download the full post.